Table of Content
1 INTRODUCTION (Page No. - 25)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.2.2 MARKETS COVERED
FIGURE 1 CLINICAL TRIAL IMAGING MARKET SEGMENTATION
1.2.3 GEOGRAPHIC SCOPE
1.2.4 YEARS CONSIDERED
1.2.5 CURRENCY CONSIDERED
1.3 LIMITATIONS
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.5.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY (Page No. - 30)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF INTERVIEWS: SUPPLY AND DEMAND SIDE
2.2.2.1 Key data from primary sources
2.2.2.2 Key industry insights
2.2.2.3 Breakdown of primary interviews
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 8 MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 LIMITATIONS
2.8 MARKET: RECESSION IMPACT
3 EXECUTIVE SUMMARY (Page No. - 43)
FIGURE 10 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MARKET, BY MODALITY, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 14 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 48)
4.1 MARKET OVERVIEW
FIGURE 15 RISING R&D SPENDING TO DRIVE MARKET GROWTH
4.2 MARKET SHARE, BY SERVICE & SOFTWARE, 2022 VS. 2028
FIGURE 16 SERVICES TO HOLD LARGEST MARKET SHARE TILL 2028
4.3 MARKET SHARE, BY MODALITY, 2023 VS. 2028
FIGURE 17 COMPUTED TOMOGRAPHY TO COMMAND LARGEST SHARE OVER FORECAST PERIOD
4.4 MARKET SHARE, BY THERAPEUTIC AREA, 2023 VS. 2028
FIGURE 18 ONCOLOGY TO DOMINATE MARKET, BY THERAPEUTIC AREA, TILL 2028
4.5 MARKET SHARE, BY END USER, 2023 VS. 2028
FIGURE 19 PHARMACEUTICAL COMPANIES TO RETAIN MARKET LEADERSHIP OVER FORECAST PERIOD
4.6 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE TILL 2028
5 MARKET OVERVIEW (Page No. - 51)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 CLINICAL TRIAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing R&D spending
5.2.1.2 Growth of pharmaceutical and biotechnology industries
5.2.1.3 Increasing number of CROs
5.2.2 RESTRAINTS
5.2.2.1 High implementation cost of imaging systems
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
5.2.4 CHALLENGES
5.2.4.1 High cost of clinical trials
5.3 PRICING ANALYSIS
TABLE 1 PRICES OF CLINICAL TRIAL IMAGING PRODUCTS (2022)
5.4 PATENT ANALYSIS
5.5 TRADE ANALYSIS
5.5.1 TRADE ANALYSIS FOR X-RAY APPARATUSES
TABLE 2 IMPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 3 EXPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION)
5.5.2 TRADE ANALYSIS FOR CT APPARATUSES
TABLE 4 IMPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 5 EXPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION)
5.6 VALUE CHAIN ANALYSIS
FIGURE 22 MARKET: VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 23 MARKET: SUPPLY CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS
FIGURE 24 MARKET: ECOSYSTEM ANALYSIS
TABLE 6 COMPANY ROLE IN ECOSYSTEM
5.9 PORTER’S FIVE FORCES ANALYSIS
TABLE 7 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 DEGREE OF COMPETITION
5.10 PESTLE ANALYSIS
5.11 REGULATORY LANDSCAPE
5.11.1 NORTH AMERICA
5.11.1.1 US
5.11.1.2 CANADA
5.11.2 EUROPE
5.11.3 ASIA PACIFIC
5.11.3.1 Japan
5.11.3.2 India
5.11.3.3 China
5.11.4 LATIN AMERICA
5.11.4.1 Brazil
5.11.4.2 Mexico
5.11.5 MIDDLE EAST
5.11.6 AFRICA
5.12 TECHNOLOGY ANALYSIS
5.13 CLINICAL TRIAL IMAGING: DISRUPTIVE TECHNOLOGIES
FIGURE 25 REVENUE SHIFT IN MARKET
6 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE (Page No. - 67)
6.1 INTRODUCTION
TABLE 8 MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
6.2 SERVICES
TABLE 9 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 10 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.1 OPERATIONAL IMAGING SERVICES
6.2.1.1 Rising number of CROs to drive market
TABLE 11 OPERATIONAL IMAGING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.2 READ ANALYSIS SERVICES
6.2.2.1 Growing clinical trial activity to support growth
TABLE 12 READ ANALYSIS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.3 SYSTEM & TECHNICAL SUPPORT SERVICES
6.2.3.1 Need for continuous technical support to drive market
TABLE 13 SYSTEM & TECHNICAL SUPPORT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.4 TRIAL DESIGN & CONSULTING SERVICES
6.2.4.1 Rising R&D spending and need for clinical trial support to boost outsourcing
TABLE 14 TRIAL DESIGN & CONSULTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3 SOFTWARE
6.3.1 HIGH EFFICIENCY AND COST-SAVING BENEFITS OF SOFTWARE TO BOOST ADOPTION
TABLE 15 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION)
7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY (Page No. - 73)
7.1 INTRODUCTION
TABLE 16 MARKET, BY MODALITY, 2021–2028 (USD MILLION)
7.2 CT
7.2.1 QUICK RESULTS AND LACK OF VISIBLE SIDE EFFECTS TO DRIVE ADOPTION
TABLE 17 MARKET FOR CT, BY REGION, 2021–2028
7.3 MRI
7.3.1 INCREASING ADOPTION OF MRI IN ONCOLOGICAL TRIALS AND STUDIES TO DRIVE MARKET
TABLE 18 MARKET FOR MRI, BY REGION, 2021–2028 (USD MILLION)
7.4 ULTRASOUND
7.4.1 HIGH SAFETY TO ENSURE CONTINUED DEMAND
TABLE 19 MARKET FOR ULTRASOUND, BY REGION, 2021–2028 (USD MILLION)
7.5 PET
7.5.1 ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS TO BOOST ADOPTION
TABLE 20 MARKET FOR PET, BY REGION, 2021–2028 (USD MILLION)
7.6 X-RAY
7.6.1 WIDE USAGE IN BONE, CHEST, AND DENTAL IMAGING TO DRIVE MARKET
TABLE 21 MARKET FOR X-RAY, BY REGION, 2021–2028 (USD MILLION)
7.7 ECHOCARDIOGRAPHY
7.7.1 ADVANTAGES IN DEFINING AND QUALIFYING POPULATIONS TO BOOST USAGE
TABLE 22 MARKET FOR ECHOCARDIOGRAPHY, BY REGION, 2021–2028 (USD MILLION)
7.8 OTHER MODALITIES
TABLE 23 MARKET FOR OTHER MODALITIES, BY REGION, 2021–2028 (USD MILLION)
8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA (Page No. - 81)
8.1 INTRODUCTION
TABLE 24 MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.2 ONCOLOGY
8.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE MARKET
TABLE 25 MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
8.3 INFECTIOUS DISEASES
8.3.1 RISING DRUG DISCOVERY ACTIVITY TO BOOST DEMAND FOR IMAGING
TABLE 26 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
8.4 NEUROLOGY
8.4.1 GROWING INVESTMENTS IN CNS DISORDER RESEARCH TO DRIVE MARKET
TABLE 27 MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
8.5 CVS DISORDERS
8.5.1 HIGH MORTALITY RATE OF CVD TO INCREASE CLINICAL TRIAL ACTIVITY
TABLE 28 MARKET FOR CVS DISORDERS, BY REGION, 2021–2028 (USD MILLION)
8.6 ENDOCRINOLOGY
8.6.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET
TABLE 29 MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)
8.7 IMMUNOLOGICAL DISORDERS
8.7.1 WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT DEMAND FOR IMAGING IN TRIALS
TABLE 30 MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
8.8 OTHER THERAPEUTIC AREAS
TABLE 31 MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)
9 CLINICAL TRIAL IMAGING MARKET, BY END USER (Page No. - 89)
9.1 INTRODUCTION
TABLE 32 MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 PHARMACEUTICAL COMPANIES
9.2.1 PHARMA COMPANIES TO HOLD LARGEST SHARE OF END-USER MARKET
FIGURE 26 RISING R&D INVESTMENTS IN PHARMACEUTICAL INDUSTRY, 2012–2026 (USD BILLION)
TABLE 33 MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION)
9.3 BIOTECHNOLOGY COMPANIES
9.3.1 RISING R&D BUDGETS OF BIOTECH COMPANIES TO DRIVE MARKET
TABLE 34 TOP BIOTECHNOLOGY INVESTMENT DEALS, 2020
TABLE 35 MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
9.4 MEDICAL DEVICE MANUFACTURERS
9.4.1 INCREASING R&D SPENDING BY MEDICAL DEVICES MANUFACTURERS TO SUPPORT GROWTH
TABLE 36 MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2021–2028 (USD MILLION)
9.5 CROS
9.5.1 INCREASING TREND OF OUTSOURCING TO DRIVE MARKET
TABLE 37 MARKET FOR CROS, BY REGION, 2021–2028 (USD MILLION)
9.6 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES
9.6.1 INCREASING RESEARCH ACTIVITY TO DRIVE MARKET
TABLE 38 MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
9.7 OTHER END USERS
TABLE 39 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
10 CLINICAL TRIAL IMAGING MARKET, BY REGION (Page No. - 97)
10.1 INTRODUCTION
TABLE 40 MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 27 NORTH AMERICA: MARKET SNAPSHOT
10.2.1 NORTH AMERICA: RECESSION IMPACT
TABLE 41 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 NORTH AMERICA: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 43 NORTH AMERICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 44 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.2 US
10.2.2.1 Rising biopharma investment to favor market growth
TABLE 45 US: PRODUCT APPROVALS IN CLINICAL TRIAL IMAGING
TABLE 46 US: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 47 US: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 48 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Rising per capita healthcare spending to drive market
TABLE 49 CANADA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 50 CANADA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 51 CANADA: CLINICAL TRIAL IMAGING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
10.3.1 EUROPE: RECESSION IMPACT
TABLE 52 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 EUROPE: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 55 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Germany to dominate market in Europe
TABLE 56 GERMANY: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 57 GERMANY: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 58 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Favorable government initiatives and growing R&D spending to drive market
TABLE 59 UK: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 60 UK: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 61 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Presence of leading pharmaceutical companies to support growth
TABLE 62 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 63 FRANCE: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 64 FRANCE: CLINICAL TRIAL IMAGING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Increasing drug approvals to ensure sustained demand for clinical trial imaging
TABLE 65 ITALY: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 66 ITALY: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 67 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Increasing biologics production to support market growth
TABLE 68 SPAIN: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 69 SPAIN: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 70 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 71 REST OF EUROPE: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 72 REST OF EUROPE: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 73 REST OF EUROPE: CLINICAL TRIAL IMAGING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 28 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET SNAPSHOT
10.4.1 ASIA PACIFIC: RECESSION IMPACT
TABLE 74 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 75 ASIA PACIFIC: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 76 ASIA PACIFIC: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 77 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.2 CHINA
10.4.2.1 China to dominate APAC market throughout forecast period
TABLE 78 CHINA: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 79 CHINA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 80 CHINA: CLINICAL TRIAL IMAGING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Rising population and healthcare expenditure to favor market growth
TABLE 81 JAPAN: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 82 JAPAN: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 83 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Rising R&D investment to boost adoption of clinical trial imaging
TABLE 84 INDIA: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 85 INDIA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 86 INDIA: CLINICAL TRIAL IMAGING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC
TABLE 87 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 88 REST OF ASIA PACIFIC: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 89 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 LOW COST OF RESOURCES, TAX ADVANTAGES TO ATTRACT PLAYER INTEREST
10.5.2 LATIN AMERICA: RECESSION IMPACT
TABLE 90 LATIN AMERICA: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 91 LATIN AMERICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 92 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 RISING RESEARCH FUNDING AND PARTNERSHIPS TO DRIVE MARKET
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 93 MIDDLE EAST & AFRICA: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
TABLE 94 MIDDLE EAST & AFRICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
TABLE 95 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 131)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 RIGHT-TO-WIN APPROACHES ADOPTED BY PLAYERS
TABLE 96 CLINICAL TRIAL IMAGING MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 29 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2022)
11.4 MARKET SHARE ANALYSIS
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 97 CLINICAL TRIAL IMAGING INDUSTRY: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX (2022)
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 31 MARKET: COMPANY EVALUATION MATRIX, 2022
11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 32 CLINICAL TRIAL IMAGING INDUSTRY: COMPANY EVALUATION MATIRX FOR STARTUPS/SMES, 2022
11.7 COMPETITIVE BENCHMARKING
FIGURE 33 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF KEY PLAYERS
TABLE 98 COMPANY PRODUCT FOOTPRINT
TABLE 99 COMPANY GEOGRAPHICAL FOOTPRINT
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 100 KEY PRODUCT LAUNCHES & APPROVALS (2020–2023)
11.8.2 DEALS
TABLE 101 KEY DEALS (2020–2023)
12 COMPANY PROFILES (Page No. - 141)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
12.1 KEY PLAYERS
12.1.1 ICON PLC.
TABLE 102 ICON PLC.: BUSINESS OVERVIEW
FIGURE 34 ICON PLC.: COMPANY SNAPSHOT (2022)
12.1.2 BIOTELEMETRY (PHILIPS)
TABLE 103 BIOTELEMETRY: BUSINESS OVERVIEW
FIGURE 35 PHILIPS GROUP: COMPANY SNAPSHOT (2022)
12.1.3 MEDPACE HOLDINGS INC.
TABLE 104 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW
FIGURE 36 MEDPACE HOLDINGS INC.: COMPANY SNAPSHOT (2022)
12.1.4 BIOMEDICAL SYSTEMS CORPORATION (ERT CLINICAL)
TABLE 105 BIOMEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW
12.1.5 BIOCLINICA INC. (CLARIO)
TABLE 106 BIOCLINICA INC.: BUSINESS OVERVIEW
12.1.6 IXICO PLC.
TABLE 107 IXICO PLC.: BUSINESS OVERVIEW
FIGURE 37 IXICO PLC.: COMPANY SNAPSHOT (2022)
12.1.7 RESONANCE HEALTH ANALYSIS SERVICES (RESONANCE HEALTH)
TABLE 108 RESONANCE HEALTH LTD.: BUSINESS OVERVIEW
FIGURE 38 RESONANCE HEALTH LTD.: COMPANY SNAPSHOT (2022)
12.1.8 RADIANT SAGE LLC
TABLE 109 RADIANT SAGE LLC: BUSINESS OVERVIEW
12.1.9 INTRINSIC IMAGING (WCG CLINICAL)
TABLE 110 WCG CLINICAL: BUSINESS OVERVIEW
12.1.10 CARDIOVASCULAR IMAGING TECHNOLOGIES
TABLE 111 CARDIOVASCULAR IMAGING TECHNOLOGIES: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 MEDICAL METRICS
12.2.2 PRISM CLINICAL IMAGING
12.2.3 BOSTON IMAGING CORE LAB
12.2.4 ANAGRAM 4 CLINICAL TRIALS
12.2.5 LYSCAUT MEDICAL IMAGING COMPANY
12.2.6 CALYX GROUP
12.2.7 BIOSPECTIVE
12.2.8 PROSCAN IMAGING
12.2.9 MICRON, INC.
12.2.10 IMAGING ENDPOINTS LI LLC.
12.2.11 PERSPECTUM
12.2.12 PHARMTRACE KLINISCHE ENTWICKLUNG GMBH
12.2.13 WORLDCARE CLINICAL
12.2.14 MEDIAN TECHNOLOGIES
12.2.15 INVICRO. LLC.
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 172)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS